Donald C. Goff, M.D.
Affiliations: | Psychiatry | New York University School of Medicine, New York, NY, United States |
Area:
Schizophrenia, Translational NeuroscienceGoogle:
"Donald Goff"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nemani K, Goff DC. (2023) Dose Finding for d-Serine Enhancement of Plasticity in Schizophrenia. Biological Psychiatry. 94: 106-107 |
| Miller BJ, Lemos H, Schooler NR, et al. (2023) Longitudinal study of inflammation and relapse in schizophrenia. Schizophrenia Research. 252: 88-95 |
| Qi W, Marx J, Zingman M, et al. (2022) Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode Schizophrenia. Schizophrenia Bulletin |
| Tuominen L, Romaniuk L, Milad MR, et al. (2021) Impairment in acquisition of conditioned fear in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Wang J, Hart KL, Qi W, et al. (2021) Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia. Journal of Clinical Psychopharmacology |
| Goff DC. (2021) The Pharmacologic Treatment of Schizophrenia-2021. Jama. 325: 175-176 |
| Su W, Zhu T, Xu L, et al. (2020) Effect of DAOA genetic variation on white matter alteration in corpus callosum in patients with first-episode schizophrenia. Brain Imaging and Behavior |
| Schoretsanitis G, Kane JM, Correll CU, et al. (2020) Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The Journal of Clinical Psychiatry. 81 |
| Kantrowitz JT, Grinband J, Goff DC, et al. (2020) Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Goff DC. (2020) Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor Binding. The New England Journal of Medicine. 382: 1555-1556 |